top of page
Dr Tobias Reichmuth talks taking hardcore science to market without biotech approval risk and the catalyst that is translational research.
One of the driving forces behind the Longevity Investors Conference is Dr Tobias Reichmuth; a company-builder since the age of 21, Reichmuth has invested in more than 20 startups and is one of the founding partners of Maximon, the longevity company building. Along with his Maximon colleague Marc P Bernegger, Reichmuth launched the Longevity Investors Conference, and we couldn’t pass up the chance to grab some time with him to discuss the current longevity market. Check out what he had to say in our video below.
bottom of page